Current analyst assessments
On this page you will find current analyst assessments of renowned research houses, which make their assessments on the business development of listed companies available for publication and distribution via our content partner EQS-Newswire.
This might be interesting for you as well
Source:
-
11 November 2024 03:00PM
Shield Therapeutics (STX) Investor Forum
Hardman & Co Video Event | Shield Therapeutics (STX)
Investor Forum
We are delighted to announce that Shield Therapeutics (STX) will be presenting at Hardman & Co's upcoming Investor Forum at 3:00pm this Thursday 14 November 2024. Register for the event to secure your place and submit questions.
A commercial-stage pharmaceutical company,...
Hardman & Co Research
Source:
-
11 September 2024 01:25PM
Focusing on successful execution
Hardman & Co Research on Shield Therapeutics (STX):
Focusing on successful execution
Shield is a commercial-stage pharma company delivering specialty products that address the unmet medical need of patients with iron deficiency (ID). Since its July 2021 US launch, Shield and Viatris have increased physician awareness of the differentiating...
Hardman & Co Research
Source:
-
23 May 2024 08:15AM
Cash management is key
Hardman & Co Research on Shield Therapeutics (STX):
Cash management is key
Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield and its partner, Viatris, have increased physician awareness...
Hardman & Co Research
Source:
-
15 November 2023 08:30AM
Accelerating effectiveness of enlarged sales team
Hardman & Co Research on Shield Therapeutics (STX):
Accelerating effectiveness of enlarged sales team
Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield has been increasing physician awa...
Hardman & Co Research
Info
The information presented here was provided by our content partner EQS. The assessments of the analyst houses were transmitted in the original via the news service EQS-Newswire for publication via the affiliated distribution networks.
Disclaimer:
The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster.
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.
If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.